Photo taken from ASCO/X
Jun 4, 2024, 16:31
Just presented at ASCO24: IMROZ results by C. Ola Landgren – ASCO
ASCO shared a post on X:
“Just presented at American Society of Clinical Oncology 2024 (ASCO24), IMROZ results- lsatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) significantly improved Progression-Free Survival (PFS) in patients with transplant-ineligible, newly diagnosed Multiple Myeloma versus Velcade, Revlimid and dexamethasone (VRd) with no new safety concerns.”
Additional information
Source: ASCO/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14